Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 4/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA7 | P43166 | 4/20 | 0.53 |
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017326 | 0.90 | CA12 (0.55) | GAACA12CA1CA2CA7 | |
| SCHEMBL304361 | 0.85 | LMNA (0.64) | GAACA12CA1CA2CA7 | |
| SCHEMBL3287847 | 0.79 | GAA (0.55) | GAAHPGDKMT2ALMNAHTT | |
| SCHEMBL311346 | 0.76 | GAA (0.51) | GAAHPGDKMT2ALMNAHTT | |
| SCHEMBL3275402 | 0.73 | LMNA (0.64) | GAAHPGDKMT2ALMNAHTT | |
| SCHEMBL8154103 | 0.71 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13065006 | 0.70 | LMNA (0.91) | GAAHPGDKMT2ALMNAHTT | |
| SCHEMBL97240 | 0.70 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12017289 | 0.69 | GAA (0.55) | GAAHPGDKMT2ALMNAHTT | |
| SCHEMBL3274787 | 0.69 | LMNA (0.52) | GAAHPGDKMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2012500834-A | — | — | 2012-01-12 | — | — | JP | claimed |
| EP-2344456-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | Xention Limited (GB) | 2011-07-20 | — | — | EP | claimed |
| US-20100087437-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| WO-2010023445-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | claimed |
| US-8258138-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| EP-2344456-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | Xention Limited (GB) | 2011-07-20 | — | — | EP | disclosed |
| US-20100087437-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010023445-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087437-A1 | Novel Potassium Channel Blockers | KCNB1, KCNJ2, KCNJ11 | GAA 3857/4885CA12 4111/4885CA1 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.